GlassScriptPhysician profile
Georgette Chekiri
NPI 1023072774
$567.10
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $200 · 2021: $153 · 2022: $94.43.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $91.89 | 2020-2021 | |
| Glaxosmithkline, LLC. | $85.50 | 2019-2020 | |
| Novo Nordisk INC | $65.18 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.82 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $47.55 | 2019-2022 | |
| Amgen INC. | $28.76 | 2019-2022 | |
| Esperion Therapeutics, INC. | $28.42 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.94 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $24.01 | 2020 | |
| Astellas Pharma US INC | $19.65 | 2019 | |
| Genentech USA, INC. | $18.24 | 2021 | |
| Allergan, INC. | $17.14 | 2020 | |
| Kaleo, INC. | $15.16 | 2021 | |
| Sanofi Pasteur INC. | $14.92 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.93 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $10.99 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Georgette Chekiri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.